Bolt Biotherapeutics, Inc. (BOLT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BOLT SEC filings page.
Bolt Biotherapeutics, Inc. (BOLT) reported $7.7M in revenue for fiscal year 2025, up 0.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Bolt remains a development-stage business: stable revenue supports little of its spending, while lower research costs have narrowed losses and cash use.
Cash conversion is straightforward but demanding: FY2025 operating cash flow of-$39.9M was close to the net loss of$33.4M , while free cash flow of-$39.9M was nearly identical because capital expenditures were only$72K . The company therefore consumes cash mainly through ongoing operations, not heavy reinvestment in physical assets.
The narrower FY2025 loss reflects spending reduction rather than commercial expansion. Revenue was essentially flat at about
Financial flexibility has diminished even as annual cash use improved. Total assets fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bolt Biotherapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bolt Biotherapeutics, Inc. held $31.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $39.9M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Bolt Biotherapeutics, Inc. scores 29/100 among other emerging companies.
Bolt Biotherapeutics, Inc. had 2M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Bolt Biotherapeutics, Inc. scores 97/100 among other emerging companies.
Bolt Biotherapeutics, Inc. spent $28.5M on research and development in fiscal year 2025, which was 65.1% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Bolt Biotherapeutics, Inc. scores 87/100 among other emerging companies.
Bolt Biotherapeutics, Inc. reported revenue of $7.7M in fiscal year 2025, against $7.7M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Bolt Biotherapeutics, Inc. scores 43/100 among other emerging companies.
Bolt Biotherapeutics, Inc.'s operations used $39.9M of cash in fiscal year 2025, against $61.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Bolt Biotherapeutics, Inc. scores 68/100 among other emerging companies.
Bolt Biotherapeutics, Inc.'s cash, cash equivalents and investments came to $31.8M at the end of fiscal year 2025, against $30.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Bolt Biotherapeutics, Inc. scores 60/100 among other emerging companies.
Bolt Biotherapeutics, Inc. scores -12.74, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.7M) relative to total liabilities ($30.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bolt Biotherapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Bolt Biotherapeutics, Inc. reported a net loss of $33.4M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bolt Biotherapeutics, Inc. generated $5K in revenue in Q2 2026. This represents a decrease of 99.7% from the same quarter a year earlier. Against the prior quarter it is down 80.8%.
Bolt Biotherapeutics, Inc.'s EBITDA was -$8.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.3% from the same quarter a year earlier. Against the prior quarter it is down 10.5%.
Bolt Biotherapeutics, Inc. reported -$7.7M in net income in Q2 2026. This represents an increase of 9.8% from the same quarter a year earlier. Against the prior quarter it is down 6.6%.
Bolt Biotherapeutics, Inc. earned -$4.57 per diluted share (EPS) in Q2 2026. This represents a decrease of 2.5% from the same quarter a year earlier. Against the prior quarter it is down 6.0%.
Cash & Balance Sheet
Bolt Biotherapeutics, Inc. held $12.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Bolt Biotherapeutics, Inc.'s ROE was -61.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 39.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 24.5 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Bolt Biotherapeutics, Inc. invested $5.1M in research and development in Q2 2026. This represents a decrease of 31.3% from the same quarter a year earlier. Against the prior quarter it is up 6.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BOLT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K-99.7% | $26K-97.9% | $2.5M | $2.2M+90.1% | $1.8M+41.5% | $1.2M-76.8% | $0-100.0% | $1.1M-54.9% |
| R&D Expenses | $5.1M-31.3% | $4.8M-49.2% | $5.0M-57.4% | $6.5M-52.6% | $7.5M-51.4% | $9.5M-42.5% | $11.7M-28.2% | $13.8M-7.8% |
| SG&A Expenses | $2.4M-31.1% | $2.8M-26.8% | $3.1M-21.0% | $3.3M-12.2% | $3.5M-27.9% | $3.8M-34.5% | $3.9M-28.7% | $3.8M-34.0% |
| Operating Income | -$8.4M+9.1% | -$7.6M+37.3% | -$7.1M+58.1% | -$7.7M+53.2% | -$9.2M+59.2% | -$12.1M+29.1% | -$16.9M+14.4% | -$16.4M+9.6% |
| EBITDA | -$8.2M+8.3% | -$7.4M+36.9% | -$6.8M+58.8% | -$7.4M+53.6% | -$8.9M+59.9% | -$11.7M+29.6% | -$16.5M+14.5% | -$15.9M+9.8% |
| Net Income | -$7.7M+9.8% | -$7.2M+34.4% | -$6.6M+58.4% | -$7.1M+52.9% | -$8.6M+59.6% | -$11.0M-2.1% | -$15.9M+11.0% | -$15.2M+6.6% |
| EPS (Basic) | -$4.57-2.5% | -$4.31+25.2% | -$3.91+53.1% | -$3.72+53.1% | -$4.46+59.9% | -$5.76-1957.1% | -$8.33-1672.3% | -$7.93-1744.2% |
| EPS (Diluted) | -$4.57-2.5% | -$4.31+25.2% | -$3.91 | -$3.72 | -$4.46 | -$5.76 | -$8.33 | -$7.93 |
| Diluted Shares (Avg) | 2M-11.8% | 2M-12.3% | N/A | 2M | 2M | 2M | N/A | 2M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
BOLT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $40.3M-46.6% | $48.0M-44.1% | $56.7M-43.0% | $65.1M-40.5% | $75.5M-39.2% | $85.9M-39.9% | $99.6M-37.6% | $109.3M-37.6% |
| Current Assets | $20.6M-46.4% | $25.8M-39.4% | $30.3M-40.4% | $35.6M-37.7% | $38.3M-50.0% | $42.5M-55.3% | $50.8M-51.9% | $57.1M-54.5% |
| Cash & Equivalents | $12.9M+33.9% | $11.6M+38.4% | $11.7M+62.4% | $17.8M+89.5% | $9.6M+54.8% | $8.4M+96.9% | $7.2M-33.3% | $9.4M+2.2% |
| Short-Term Investments | $4.7M-81.2% | $11.3M-62.9% | $15.8M-60.6% | $14.2M-68.1% | $25.2M-62.7% | $30.4M-65.0% | $40.1M-56.1% | $44.4M-59.8% |
| Long-Term Investments | $509K-96.3% | $1.0M-94.7% | $4.3M-81.0% | $6.9M-77.4% | $13.7M-42.4% | $19.1M-10.9% | $22.9M-13.4% | $30.6M+41.4% |
| Total Liabilities | $27.7M-24.4% | $28.2M-27.8% | $30.2M-28.7% | $33.0M-11.7% | $36.7M-4.3% | $39.1M+0.8% | $42.4M-9.8% | $37.3M-20.8% |
| Current Liabilities | $7.9M-36.1% | $7.3M-45.9% | $8.4M-46.8% | $10.0M-44.9% | $12.3M-31.2% | $13.6M-18.9% | $15.9M-22.5% | $18.1M-3.6% |
| Non-Current Liabilities | $19.8M-18.5% | $20.9M-18.2% | $21.8M-17.9% | $23.0M+19.6% | $24.3M+19.3% | $25.5M+15.8% | $26.6M0.0% | $19.2M-32.2% |
| Total Equity | $12.6M-67.5% | $19.8M-57.7% | $26.5M-53.7% | $32.1M-55.4% | $38.8M-54.8% | $46.8M-55.1% | $57.2M-49.3% | $72.0M-43.8% |
| Retained Earnings | -$475.7M-6.4% | -$468.0M-6.7% | -$460.8M-7.8% | -$454.1M-10.4% | -$447.0M-12.8% | -$438.4M-16.9% | -$427.4M-17.3% | -$411.5M-18.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BOLT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.5M+31.9% | -$8.0M+40.0% | -$7.2M+50.4% | -$9.7M+30.3% | -$9.6M+40.5% | -$13.4M+20.2% | -$14.4M-1.2% | -$14.0M+16.6% |
| Depreciation & Amortization | $200K-33.3% | $203K-49.1% | $255K-40.1% | $300K-40.0% | $300K-25.0% | $399K-12.9% | $426K-8.8% | $500K0.0% |
| Stock-Based Compensation | $552K-11.7% | $545K-23.1% | N/A | $407K-62.9% | $625K-77.9% | $709K-69.2% | N/A | $1.1M-52.9% |
| Capital Expenditures | N/A | N/A | $0 | $72K+75.6% | N/A | N/A | $0-100.0% | $41K-75.2% |
| Free Cash Flow | N/A | N/A | -$7.2M+50.4% | -$9.8M+30.0% | N/A | N/A | -$14.4M-1.1% | -$14.0M+17.2% |
| Investing Cash Flow | $7.8M-28.0% | $7.9M-45.6% | $1.1M-91.2% | $17.9M+4.4% | $10.8M-40.0% | $14.6M+42.6% | $12.2M-22.6% | $17.1M+35.4% |
| Financing Cash Flow | $19K+35.7% | $6K | $5K-82.8% | $0 | $14K-82.3% | $0 | $29K-72.6% | $0 |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BOLT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -167480.0% | -29234.6% | -283.4% | -355.1% | -510.5% | -991.4% | N/A | -1441.1% |
| Net Margin | -154400.0% | -27861.5% | -265.2% | -329.4% | -474.6% | -903.4% | N/A | -1330.1% |
| Return on Equity | -61.1%-39.0pp | -36.5%-13.0pp | -25.0%+2.8pp | -22.3%-1.2pp | -22.0%+2.6pp | -23.6%-13.2pp | -27.9%-12.0pp | -21.1%-8.4pp |
| Return on Assets | -19.1%-7.8pp | -15.1%-2.2pp | -11.7%+4.3pp | -11.0%+2.9pp | -11.3%+5.7pp | -12.9%-5.3pp | -16.0%-4.8pp | -13.9%-4.6pp |
| Current Ratio | 2.61-0.5x | 3.51+0.4x | 3.59+0.4x | 3.57+0.4x | 3.11-1.2x | 3.13-2.5x | 3.20-2.0x | 3.16-3.5x |
| Debt-to-Equity | 2.19+1.2x | 1.42+0.6x | 1.14+0.4x | 1.03+0.5x | 0.94+0.5x | 0.83+0.5x | 0.74+0.3x | 0.52+0.2x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.040.0x | 0.030.0x | 0.020.0x | 0.010.0x | 0.000.0x | 0.010.0x |
| FCF Margin | N/A | N/A | -286.2% | -452.0% | N/A | N/A | N/A | -1227.6% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. BOLT | FY2025 | $7.7M | -$33.4M | N/A | $6.7M | 64/100 |
| Ernexa Therapeutics Inc. ERNA | FY2025 | N/A | -$14.1M | N/A | $3.5M | — |
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | $13.6M | N/A | $4.5M | — |
| Sensei Biotherapeutics, Inc. SNSE | FY2025 | N/A | -$21.1M | N/A | $18.6M | — |
| Intensity Therapeutics, Inc. INTS | FY2025 | N/A | -$11.6M | N/A | $11.2M | — |
| LYRA THERAPEUTICS INC LYRA | FY2025 | $398K | -$28.9M | N/A | $2.3M | — |
Where Bolt Biotherapeutics, Inc. Ranks
Frequently Asked Questions
What is Bolt Biotherapeutics, Inc.'s annual revenue?
Bolt Biotherapeutics, Inc. (BOLT) reported $7.7M in total revenue for fiscal year 2025. This represents a 0.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bolt Biotherapeutics, Inc.'s revenue growing?
Bolt Biotherapeutics, Inc. (BOLT) revenue grew by 0.1% year-over-year, from $7.7M to $7.7M in fiscal year 2025.
Is Bolt Biotherapeutics, Inc. profitable?
No, Bolt Biotherapeutics, Inc. (BOLT) reported a net income of -$33.4M in fiscal year 2025.
What is Bolt Biotherapeutics, Inc.'s EBITDA?
Bolt Biotherapeutics, Inc. (BOLT) had EBITDA of -$34.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bolt Biotherapeutics, Inc.'s return on equity (ROE)?
Bolt Biotherapeutics, Inc. (BOLT) has a return on equity of -125.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bolt Biotherapeutics, Inc.'s free cash flow?
Bolt Biotherapeutics, Inc. (BOLT) recorded an outflow of $39.9M in free cash flow during fiscal year 2025. This represents a 34.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bolt Biotherapeutics, Inc.'s operating cash flow?
Bolt Biotherapeutics, Inc. (BOLT) recorded an outflow of $39.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bolt Biotherapeutics, Inc.'s total assets?
Bolt Biotherapeutics, Inc. (BOLT) had $56.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bolt Biotherapeutics, Inc.'s capital expenditures?
Bolt Biotherapeutics, Inc. (BOLT) invested $72K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bolt Biotherapeutics, Inc. spend on research and development?
Bolt Biotherapeutics, Inc. (BOLT) invested $28.5M in research and development during fiscal year 2025.
What is Bolt Biotherapeutics, Inc.'s current ratio?
Bolt Biotherapeutics, Inc. (BOLT) had a current ratio of 3.59 as of fiscal year 2025, which is generally considered healthy.
What is Bolt Biotherapeutics, Inc.'s debt-to-equity ratio?
Bolt Biotherapeutics, Inc. (BOLT) had a debt-to-equity ratio of 1.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bolt Biotherapeutics, Inc.'s return on assets (ROA)?
Bolt Biotherapeutics, Inc. (BOLT) had a return on assets of -58.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bolt Biotherapeutics, Inc.'s P/E ratio?
Bolt Biotherapeutics, Inc. (BOLT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $6.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bolt Biotherapeutics, Inc.'s price-to-sales ratio?
Bolt Biotherapeutics, Inc. (BOLT) trades at 1.4x sales, its market capitalization divided by revenue of $4.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $6.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Bolt Biotherapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Bolt Biotherapeutics, Inc. (BOLT) held $31.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $39.9M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Bolt Biotherapeutics, Inc.'s Altman Z-Score?
Bolt Biotherapeutics, Inc. (BOLT) has an Altman Z-Score of -12.74, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bolt Biotherapeutics, Inc.'s Piotroski F-Score?
Bolt Biotherapeutics, Inc. (BOLT) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bolt Biotherapeutics, Inc.'s earnings high quality?
Bolt Biotherapeutics, Inc. (BOLT) reported a net loss of $33.4M while operations used $39.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bolt Biotherapeutics, Inc.?
Bolt Biotherapeutics, Inc. (BOLT) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.